Dennis R. Burton

Dennis R. Burton

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Dennis R. Burton

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2009 in Science
Verified
Journal Article
Closed access
PDF file
LWLaura M. Walker
Laura M. Walker
SPSanjay K. Phogat
Sanjay K. Phogat
PCPo-Ying Chan-Hui
Po-Ying Chan-Hui
DWDenise Wagner
Denise Wagner
PPPham Phung
Pham Phung
DBDennis R. Burton
Dennis R. Burton
Anti-HIV Antibodies: One of the top priorities for an HIV vaccine is the ability to elicit a broadly neutralizing antibody response, which should provide the best protection against infection. In the 25 years since the discovery of HIV, very few broadly neutralizing antibodies have been identified, and those that do exist were discovered nearly two decades ago. Using a high-throughput culture system, Walker et al. (p. 285 ; published online 3 September) now identify two additional broadly neutralizing antibodies isolated from a clade A HIV-infected African donor. These antibodies exhibit great potency and, in contrast to other known broadly neutralizing antibodies, are able to neutralize a wide range of viruses from many different clades. The antibodies recognize a motif in the trimerized viral envelope protein that is found in conserved regions of the variable loops of the gp120 subunit. Identification of this motif provides an intriguing new target for vaccine development.

22 September 2011 in Nature
Verified
Journal Article
Open access
PDF file
LWLaura M. Walker
Laura M. Walker
MHMichael Huber
Michael Huber
KDKatie J. Doores
Katie J. Doores
EFEmilia Falkowska
Emilia Falkowska
RPRobert Pejchal
Robert Pejchal
PPPascal Poignard
Pascal Poignard
Broadly neutralizing antibodies against highly variable viral pathogens are much sought after to treat or protect against global circulating viruses. Here we probed the neutralizing antibody repertoires of four human immunodeficiency virus (HIV)-infected donors with remarkably broad and potent neutralizing responses and rescued 17 new monoclonal antibodies that neutralize broadly across clades. Many of the new monoclonal antibodies are almost tenfold more potent than the recently described PG9, PG16 and VRC01 broadly neutralizing monoclonal antibodies and 100-fold more potent than the original prototype HIV broadly neutralizing monoclonal antibodies1,2,3. The monoclonal antibodies largely recapitulate the neutralization breadth found in the corresponding donor serum and many recognize novel epitopes on envelope (Env) glycoprotein gp120, illuminating new targets for vaccine design. Analysis of neutralization by the full complement of anti-HIV broadly neutralizing monoclonal antibodies now available reveals that certain combinations of antibodies should offer markedly more favourable coverage of the enormous diversity of global circulating viruses than others and these combinations might be sought in active or passive immunization regimes. Overall, the isolation of multiple HIV broadly neutralizing monoclonal antibodies from several donors that, in aggregate, provide broad coverage at low concentrations is a highly positive indicator for the eventual design of an effective antibody-based HIV vaccine.

21 August 2020 in Science
Verified
Journal Article
Open access
PDF file
TRThomas F. Rogers
Thomas F. Rogers
FZFangzhu Zhao
Fangzhu Zhao
DHDeli Huang
Deli Huang
NBNathan Beutler
Nathan Beutler
ABAlison Burns
Alison Burns
DBDennis R. Burton
Dennis R. Burton
Protective neutralizing antibodies: Antibodies produced by survivors of coronavirus disease 2019 (COVID-19) may be leveraged to develop therapies. A first step is identifying neutralizing antibodies, which confer strong protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Rogers et al. used a high-throughput pipeline to isolate and characterize monoclonal antibodies from convalescent donors. Antibodies were selected for binding to the viral spike protein, which facilitates entry into host cells by binding to the angiotensin-converting enzyme 2 (ACE2) receptor. Most isolated antibodies bound to regions of the spike outside of the receptor binding domain (RBD); however, a larger proportion of the RBD-binding antibodies were neutralizing, with the most potent binding at a site that overlaps the ACE2 binding site. Two of the neutralizing antibodies were tested in Syrian hamsters and provided protection against SARS-CoV-2 infection. Science , this issue p. 956

25 November 2011 in Science
Verified
Journal Article
Closed access
PDF file
RPRobert Pejchal
Robert Pejchal
KDKatie J. Doores
Katie J. Doores
LWLaura M. Walker
Laura M. Walker
RKReza Khayat
Reza Khayat
PHPo-Ssu Huang
Po-Ssu Huang
IWIan A. Wilson
Ian A. Wilson
The HIV envelope (Env) protein gp120 is protected from antibody recognition by a dense glycan shield. However, several of the recently identified PGT broadly neutralizing antibodies appear to interact directly with the HIV glycan coat. Crystal structures of antigen-binding fragments (Fabs) PGT 127 and 128 with Man9 at 1.65 and 1.29 angstrom resolution, respectively, and glycan binding data delineate a specific high mannose-binding site. Fab PGT 128 complexed with a fully glycosylated gp120 outer domain at 3.25 angstroms reveals that the antibody penetrates the glycan shield and recognizes two conserved glycans as well as a short β-strand segment of the gp120 V3 loop, accounting for its high binding affinity and broad specificify. Furthermore, our data suggest that the high neutralization potency of PGT 127 and 128 immunoglobulin Gs may be mediated by cross-linking Env trimers on the viral surface.

21 January 2019 in Nature
Verified
Journal Article
Closed access
PDF file
BBBryan Briney
Bryan Briney
AIAnne Inderbitzin
Anne Inderbitzin
CJCollin Joyce
Collin Joyce
DBDennis R. Burton
Dennis R. Burton

15 November 2001 in Journal of Virology
Verified
Journal Article
Open access
PDF file
MZMichael B. Zwick
Michael B. Zwick
ALAran F. Labrijn
Aran F. Labrijn
MWMeng Wang
Meng Wang
CSCatherine Spenlehauer
Catherine Spenlehauer
ESErica Ollmann Saphire
Erica Ollmann Saphire
PPPaul W. H. I. Parren
Paul W. H. I. Parren
The identification and epitope mapping of broadly neutralizing anti-human immunodeficiency virus type 1 (HIV-1) antibodies (Abs) is important for vaccine design, but, despite much effort, very few such Abs have been forthcoming. Only one broadly neutralizing anti-gp41 monoclonal Ab (MAb), 2F5, has been described. Here we report on two MAbs that recognize a region immediately C-terminal of the 2F5 epitope. Both MAbs were generated from HIV-1-seropositive donors, one (Z13) from an antibody phage display library, and one (4E10) as a hybridoma. Both MAbs recognize a predominantly linear and relatively conserved epitope, compete with each other for binding to synthetic peptide derived from gp41, and bind to HIV-1 MN virions. By flow cytometry, these MAbs appear to bind relatively weakly to infected cells and this binding is not perturbed by pretreatment of the infected cells with soluble CD4. Despite the apparent linear nature of the epitopes of Z13 and 4E10, denaturation of recombinant envelope protein reduces the binding of these MAbs, suggesting some conformational requirements for full epitope expression. Most significantly, Z13 and 4E10 are able to neutralize selected primary isolates from diverse subtypes of HIV-1 (e.g., subtypes B, C, and E). The results suggest that a rather extensive region of gp41 close to the transmembrane domain is accessible to neutralizing Abs and could form a useful target for vaccine design.